GenomeQuest Forms Clinical Advisory Board

WESTBOROUGH, Mass., Oct 20, 2011 (BUSINESS WIRE) -- GenomeQuest Inc., a global provider of large-scale genomic software applications, today announced the appointment of three charter members to its clinical advisory board. The board will provide expert perspectives across science, medicine and technology related to the broad use of genomics in health care delivery by academic research centers, commercial and academic diagnostic labs, health clinics and hospitals.

The GenomeQuest clinical advisory board includes the following key opinion leaders:

Heidi Rehm, Ph.D., FACMG Rehm is a board-certified clinical molecular geneticist and Assistant Professor of Pathology at Harvard Medical School with appointments at Brigham & Women's Hospital, Massachusetts General Hospital and Children's Hospital Boston. She is also the director of the Laboratory for Molecular Medicine at the Partners HealthCare Center for Personalized Medicine. Rehm has served as the Director of the ABMG Clinical Molecular Genetics Training Program at Harvard Medical School since 2006 and conducts research into hearing loss, Usher syndrome, cardiomyopathy and the use of IT in enabling personalized medicine.

Madhuri Hegde, Ph.D., FACMG Hegde is an Associate Professor at the Emory University School of Medicine Department of Human Genetics and the Scientific Director of the Emory Genetics Laboratory. The primary focus of Dr. Hegde's clinical work is the development of high-throughput sequencing strategies for rare disorders using sequence capture technologies, robotics, next-generation sequencing, oligonucleotide array platforms, robotics and using predictive analysis tools and biological testing. Her research focuses on functional analysis of sequence variants in disease associated genes, specifically mental retardation and muscular dystrophies, and translating what is learned in the basic research laboratory to clinical practice.

Shashikant Kulkarni, Ph.D., FACMG Kulkarni is the Medical Director of Genomics and Pathology Services and Medical Director of Cytogenomics and Molecular Pathology at Washington University School of Medicine in St. Louis. He is an Associate Professor in the departments of Pathology & Immunology, Pediatrics and Genetics. In his role, Dr. Kulkarni oversees one of the most modern CLIA certified and CAP accredited state-of-art full-service academic cytogenomics and molecular pathology laboratories in the country. The lab utilizes cytogenetics, FISH, chromosomal microarray, Sanger sequencing and next-generation sequencing methodology for clinical diagnostic testing. This laboratory has been at the forefront in implementing molecular genomic methods in clinical diagnostic testing for clinical genomics testing performed on all tissue types for diagnosis of congenital anomalies and mental retardation; leukemias, lymphomas and other hematological disorders; and solid neoplasms. These tests include prenatal diagnostics, perinatal and childhood studies in the evaluation of congenital and developmental disorders, infertility and pregnancy loss studies and cancer. Dr. Kulkarni is leading multi-institutional efforts to characterize gold standard reference materials for clinical chromosomal microarray and is actively involved in defining standards for next generation sequencing in clinical diagnostics through his collaboration with the Centers for Disease Control and Prevention through the Clinical Next-Generation-Sequencing Quality Standards National Working Group. He also serves on the Scientific Advisory Board of NIH Institute - National Institute of General Medical Science's Coriell Institute. Dr Kulkarni is the program director of the Medical Genetics training program at Washington University School of Medicine and conducts research in genomics of multiple myeloma and acute myeloid leukemia.

About GenomeQuest

GenomeQuest is a global provider of large-scale genomic software applications. Based on a whole/multi-genome hosting platform, the company's products include GQ-IP for global research of genomic sequence intellectual property, GQ-Dx, the industry's first clinical decision-support system for whole-genome diagnostics, and GQ-Research, a research platform for teams to store, manage and analyze genomic information at whole/multi-genome scale. GenomeQuest serves major pharmaceutical companies, global agriculture firms, biotech firms, IP legal groups, genome centers, academic research centers, diagnostic companies and labs and universities around the world.

Learn more at www.genomequest.com .

SOURCE: GenomeQuest Inc.

 

Suggested Articles

Moderna’s shares shrunk by nearly 5% before the long holiday weekend Thursday after a report out by Stat said the biotech was delaying its trial.

Keep your post-pandemic trials on track: learn how the right clinical supply chain partner can help sponsors avoid trial disruption. Read now>>

Helsinn Group and MEI Pharma penned a near $500 million biobucks pact for experimental blood cancer drug pracinostat back in 2016.